Synopsis: Despite at least 1 large trial showing benefit, the use of neuromuscular blockade during treatment of acute respiratory distress syndrome has never become routine. This trial evaluates 90-day mortality after randomization to either early neuromuscular blockade or usual low target sedation.
Source: National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network, Moss M, Huang DT, Brower RG, et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med. 2019;380:1997–2008.
Disclosure: The authors declare that they have no conflicts of interest.